Dianthus price target raised to $103 from $80 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Dianthus (DNTH) to $103 from $80 and keeps an Outperform rating on the shares. Following the completion of the recent Dianthus secondary offering, the firm is incorporating the $675M raise in its estimates and assumes exercise of the overallotment. While Wedbush awaits more detailed data from CAPTIVATE, the firm anticipates a more favorable response rate and convenient dosing vs. riliprubart, which should make claseprubart competitive in CIDP.